US Patent Issued to Guardant Health on June 3 for "Gene mutations and copy number alterations of EGFR, KRAS and MET" (Texas, California Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,319,968, issued on June 3, was assigned to Guardant Health Inc. (Palo Alto, Calif.).

"Gene mutations and copy number alterations of EGFR, KRAS and MET" was invented by Scott Kopetz (Austin, Texas) and AmirAli Talasaz (Atherton, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer."

The patent was filed on July 22, 2021, under Application No. 17/383,390.

*For further information, including images...